Market Research Logo

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026

Summary

Dry Eye Syndrome (DES) is a multifactorial disease of the tears and ocular surface that causes ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surfaceand there are currently very few approved treatment options for Dry Eye Syndrome (DES) patients.Dry Eye Syndrome (DES)pipeline activity comprises 10 active Phase III (or Phase II/III) pipeline agents with novel mechanisms of action as well as cyclosporines with improved clinical profiles. It is expected that these new drugs will expand the Dry Eye Syndrome (DES) treatment options and contribute to overall market growth. Nevertheless, considerable opportunities remain within the severely underserved Dry Eye Syndrome (DES) market.

With a rapidly accelerating worldwide prevalence and the limited treatment options available, there is a growing pressure for new therapies and curative treatmentwithin the Dry Eye Syndrome (DES) market to treat this multifactorial ocular condition. Historically, many companies have failed to bring novel Dry Eye Syndrome (DES) drug candidates through clinical development programs, including numerous failures in Phase III clinical trials. This high failure rate has led to a scarcity of Dry Eye Syndrome (DES) drugs available. However, this is expected to change over the forecast period, with new drugs anticipated to enter all markets within the 8MM (US, France, Germany, Italy, Spain, the UK, Japan and China).

This change has already been initiated with the recent arrivals of Shire’s Xiidra (lifitegraft) and Santen’s Ikervis (cyclosporine) in the US and Europe. Furthermore, additional marketing approvals for currently marketed Dry Eye Syndrome (DES) drugs,in new countries in the 8MM, will provide a source of growth in this market. It is estimated that the 2016 sales for Dry Eye Syndrome (DES) was approximately $2.2B across the 8MM(US, France, Germany, Italy, Spain, the UK, Japan and China).

The research report Dry Eye Syndrome: Global Drug Forecast and Market Analysis to 2026, provides an overview of Dry Eye Syndrome (DES), including epidemiology, etiology, pathophysiology, as well current Dry Eye Syndrome (DES) therapeutic recommendations of all 8MM (US, France, Germany, Italy, Spain, the UK, Japan and China) covered.

In particular, this report helps to -

  • Assess the current competitive landscape and its evolution over the forecast period.
  • Evaluate the significance of the late-stage pipeline products entering the Dry Eye Syndrome (DES) market and how these products will impact the future treatment landscape.
  • Highlight the significant unmet needs in the Dry Eye Syndrome (DES) market.
  • Identify any remaining opportunities in the Dry Eye Syndrome (DES) market.
  • Assess the varying approaches to treatment in the different markets in the 8MM.
Companies Mentioned: Akorn, Alcon, Aldeyra, Allergan, Altacor, Apotex, Argentum Pharmaceuticals, Aspire, Auven Therapeutics, Bausch & Lomb, Chongqing Santen Kerui Pharmaceutical, Dompe, Famy Care Limited, G-TreeBNT, Greenstone, Intrexon Corporation, Kaken, Kala Pharmaceuticals, Kyorin, LaboratoiresThea, Lee’s Pharmaceutical, LubrisBiopharma, Magenta, MC2 Therapeutics, Mitotech, Mylan, Moorfield Pharmaceuticals, Nippon, Nissiin, Novaliq, Novartis, Otsuka, Parion Sciences, Pfizer, Pfizer’s InnoPharma, PharmaMar, Rayner, RegeneRx, Santen, Scope Ophthalmics, Seikagaku, Senju, Shire, Sun Pharmaceutical, Sylentis, Thea, Toa, Twi Pharmaceuticals, United Laboratories, Ursapharm, Wakamoto, Wockhardt.

Scope
  • Overview of DES: including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
  • Annualized DES market revenue, cost of therapy per patient, and treatment usage patterns in three patient segments (including mild DES, moderate DES, and severe DES), forecast from 2016 to 2026.
  • Key topics covered: strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the DES therapeutics market
  • Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for DES therapy. The most promising candidate in Phase III (and Phase II/III) development is profiled.
  • Analysis of the current and future market competition in the global DES therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy

The report will enable you to -
  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global DES therapeutics market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global DES therapeutics market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 DES: Executive Summary
2.1 DES Therapeutics Market Will Grow to $5.6B by 2026
2.2 DES Is a High Risk Indication for Drug Development
2.3 While New Therapeutics Enter the DES Market, Unmet Needs Persist
2.4 Significant Opportunities Remain Within the DES Market to Fulfill Unmet Needs
2.5 Newly Approved Therapeutics Will Improve Treatment Options for DES Patients
2.6 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.2 Disease Classification
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.5 Epidemiological Forecast for DES (2016-2026)
5.6 Discussion
6 Disease Management
6.1 Diagnosis and Treatment Overview
6.2 US
6.3 5EU
6.4 Japan
6.5 China
7 Competitive Assessment
7.1 Overview
7.2 Marketed Therapies and Artificial Tears for DES
7.3 Other Therapies
8 Unmet Needs and Opportunity Assessment
8.1 Overview
8.2 New Therapies for DES
8.3 Better Diagnostic Tools
8.4 Appropriate Clinical Trial Design
8.5 Simplified Dosing
9 Pipeline Assessment
9.1 Overview
9.2 Promising Drugs in Clinical Development
9.3 Promising Drugs in Early-Stage Development
10 Current and Future Players
10.1 Overview
10.2 Trends in Corporate Strategy
10.3 Allergan
10.4 Santen
10.5 Shire
10.6 RegeneRx
10.7 Aldeyra
10.8 Sylentis
10.9 Sun Pharmaceutical
10.10 Novartis
10.11 Dompe
11 Market Outlook
11.1 Global Markets
11.2 US
11.3 5EU
11.4 Japan
11.5 China
12 Appendix
12.1 Bibliography
12.2 Abbreviations
12.3 Methodology
12.4 Primary Research - Key Opinion Leaders Interviewed for This Report
12.5 Primary Research - Prescriber Survey
12.6 About the Authors
12.7 About GlobalData
12.8 Contact Us
12.9 Disclaimer
1.1 List of Tables
Table 1: DES: Key Metrics in the 8MM
Table 2: Risk Factors and Comorbid Conditions Associated with DES
Table 3: Diagnostic Tests for DES
Table 4: Popular Validated Questionnaires for DES
Table 5: Treatment Guidelines for DES
Table 6: Country Profile - US
Table 7: Country Profile - 5EU
Table 8: Country Profile - Japan
Table 9: Country Profile - China
Table 10: Leading Treatments for DES, 2018
Table 11: Comparison of Therapeutic Classes in Development for DES, 2016-2026
Table 12: Key Companies in the DES Market in the 8MM, 2017
Table 13: Allergan’s DES Portfolio Assessment, 2018
Table 14: Santen’s DES Portfolio Assessment, 2018
Table 15: Shire’s DES Portfolio Assessment, 2018
Table 16: RegeneRx’s DES Portfolio Assessment, 2018
Table 17: Aldeyra’s DES Portfolio Assessment, 2018
Table 18: Sylentis’ DES Portfolio Assessment, 2018
Table 19: Sun Pharma’s DES Portfolio Assessment, 2018
Table 20: Novartis’ DES Portfolio Assessment, 2018
Table 21: Dompe’s DES Portfolio Assessment, 2018
Table 22: DES Market - Global Drivers and Barriers, 2016-2026
Table 23: Key Events Impacting Sales for DES in the US, 2016-2026
Table 24: DES Market - Drivers and Barriers in the US, 2016-2026
Table 25: Key Events Impacting Sales for DES in the 5EU, 2016-2026
Table 26: DES Market - Drivers and Barriers in the 5EU, 2016-2026
Table 27: Key Events Impacting Sales for DES in Japan, 2016-2026
Table 28: DES Market - Global Drivers and Barriers in Japan, 2016-2026
Table 29: Key Events Impacting Sales for DES in China, 2016-2026
Table 30: DES Market - Global Drivers and Barriers in China, 2016-2026
Table 31: Key Historical and Projected Launch Dates for DES
Table 32: Key Historical and Projected Patent Expiry Dates for DES
Table 33: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: Global Sales Forecast by Country for DES in 2016 and 2026
Figure 2: Analysis of the Company Portfolio Gap in DES During the Forecast Period
Figure 3: Vicious Circle of DES
Figure 4: Tear Film Structure
Figure 5: Classification of DES
Figure 6: 8MM, Age-Standardized Total Prevalence of DES (%), Both Sexes, Ages ≥20 Years, 2016
Figure 7: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of DES
Figure 8: 8MM, Total Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016
Figure 9: 8MM, Age-Specific Total Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016
Figure 10: 8MM, Sex-Specific Total Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016
Figure 11: 8MM, Diagnosed Prevalent Cases of DES, Both Sexes, Ages ≥20 Years, N, 2016
Figure 12: Unmet Needs and Opportunities in DES
Figure 13: Bullseye Diagram of Products in Clinical Development for DES, 2016
Figure 14: Key Phase IIb/III Trials for the Promising Pipeline Agents that GlobalData Expects be Licensed for DES in the 8MM During the Forecast Period
Figure 15: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to be Licensed for the Treatment of DES During the Forecast Period
Figure 16: Analysis of the Company Portfolio Gap in DES During the Forecast Period
Figure 17: Global (8MM) Sales Forecast by Country for DES in 2016 and 2026
Figure 18: Sales Forecast by Class for DES in the US in 2016 and 2026
Figure 19: Sales Forecast by Class for DES in the 5EU in 2016 and 2026
Figure 20: Sales Forecast by Class for DES in Japan in 2016 and 2026
Figure 21: Sales Forecast by Class for DES in China in 2016 and 2026

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report